NASDAQ:IPA

ImmunoPrecise Antibodies Competitors

$12.31
+0.03 (+0.24 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$11.57
Now: $12.31
$12.95
50-Day Range
$8.84
MA: $11.66
$16.07
52-Week Range
$2.68
Now: $12.31
$33.34
Volume167,374 shs
Average Volume115,295 shs
Market Capitalization$235.35 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

ImmunoPrecise Antibodies (NASDAQ:IPA) Vs. PHVS, FDMT, GRCL, ITOS, PHAR, and FNCH

Should you be buying IPA stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to ImmunoPrecise Antibodies, including Pharvaris B.V. (PHVS), 4D Molecular Therapeutics (FDMT), Gracell Biotechnologies (GRCL), iTeos Therapeutics (ITOS), Pharming Group (PHAR), and Finch Therapeutics Group (FNCH).

Pharvaris B.V. (NASDAQ:PHVS) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Pharvaris B.V. and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pharvaris B.V.N/AN/AN/A
ImmunoPrecise AntibodiesN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for Pharvaris B.V. and ImmunoPrecise Antibodies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pharvaris B.V.01302.75
ImmunoPrecise Antibodies01002.00

Pharvaris B.V. currently has a consensus target price of $47.50, indicating a potential upside of 63.76%. Given Pharvaris B.V.'s stronger consensus rating and higher probable upside, analysts plainly believe Pharvaris B.V. is more favorable than ImmunoPrecise Antibodies.

Valuation & Earnings

This table compares Pharvaris B.V. and ImmunoPrecise Antibodies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pharvaris B.V.N/AN/AN/AN/AN/A
ImmunoPrecise AntibodiesN/AN/AN/AN/AN/A

Summary

Pharvaris B.V. beats ImmunoPrecise Antibodies on 3 of the 3 factors compared between the two stocks.

4D Molecular Therapeutics (NASDAQ:FDMT) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares 4D Molecular Therapeutics and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
4D Molecular TherapeuticsN/AN/AN/A
ImmunoPrecise AntibodiesN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for 4D Molecular Therapeutics and ImmunoPrecise Antibodies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
4D Molecular Therapeutics01202.67
ImmunoPrecise Antibodies01002.00

4D Molecular Therapeutics currently has a consensus target price of $45.50, indicating a potential upside of 32.19%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than ImmunoPrecise Antibodies.

Valuation & Earnings

This table compares 4D Molecular Therapeutics and ImmunoPrecise Antibodies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D Molecular TherapeuticsN/AN/AN/AN/AN/A
ImmunoPrecise AntibodiesN/AN/AN/AN/AN/A

Summary

4D Molecular Therapeutics beats ImmunoPrecise Antibodies on 3 of the 3 factors compared between the two stocks.

Gracell Biotechnologies (NASDAQ:GRCL) and ImmunoPrecise Antibodies (NASDAQ:IPA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Gracell Biotechnologies and ImmunoPrecise Antibodies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gracell BiotechnologiesN/AN/AN/A
ImmunoPrecise AntibodiesN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for Gracell Biotechnologies and ImmunoPrecise Antibodies, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gracell Biotechnologies00403.00
ImmunoPrecise Antibodies01002.00

Gracell Biotechnologies currently has a consensus target price of $34.50, indicating a potential upside of 148.38%. Given Gracell Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe Gracell Biotechnologies is more favorable than ImmunoPrecise Antibodies.

Valuation & Earnings

This table compares Gracell Biotechnologies and ImmunoPrecise Antibodies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gracell BiotechnologiesN/AN/AN/AN/AN/A
ImmunoPrecise AntibodiesN/AN/AN/AN/AN/A

Summary

Gracell Biotechnologies beats ImmunoPrecise Antibodies on 3 of the 3 factors compared between the two stocks.

ImmunoPrecise Antibodies (NASDAQ:IPA) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for ImmunoPrecise Antibodies and iTeos Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoPrecise Antibodies01002.00
iTeos Therapeutics00503.00

iTeos Therapeutics has a consensus target price of $49.40, indicating a potential upside of 103.54%. Given iTeos Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe iTeos Therapeutics is more favorable than ImmunoPrecise Antibodies.

Earnings and Valuation

This table compares ImmunoPrecise Antibodies and iTeos Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoPrecise AntibodiesN/AN/AN/AN/AN/A
iTeos TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares ImmunoPrecise Antibodies and iTeos Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoPrecise AntibodiesN/AN/AN/A
iTeos TherapeuticsN/AN/AN/A

Insider & Institutional Ownership

71.1% of iTeos Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

iTeos Therapeutics beats ImmunoPrecise Antibodies on 4 of the 4 factors compared between the two stocks.

ImmunoPrecise Antibodies (NASDAQ:IPA) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for ImmunoPrecise Antibodies and Pharming Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoPrecise Antibodies01002.00
Pharming Group0000N/A

Earnings and Valuation

This table compares ImmunoPrecise Antibodies and Pharming Group's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoPrecise AntibodiesN/AN/AN/AN/AN/A
Pharming GroupN/AN/AN/AN/AN/A

Profitability

This table compares ImmunoPrecise Antibodies and Pharming Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoPrecise AntibodiesN/AN/AN/A
Pharming GroupN/AN/AN/A

ImmunoPrecise Antibodies (NASDAQ:IPA) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for ImmunoPrecise Antibodies and Finch Therapeutics Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoPrecise Antibodies01002.00
Finch Therapeutics Group0000N/A

Earnings and Valuation

This table compares ImmunoPrecise Antibodies and Finch Therapeutics Group's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoPrecise AntibodiesN/AN/AN/AN/AN/A
Finch Therapeutics GroupN/AN/AN/AN/AN/A

Profitability

This table compares ImmunoPrecise Antibodies and Finch Therapeutics Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoPrecise AntibodiesN/AN/AN/A
Finch Therapeutics GroupN/AN/AN/A


ImmunoPrecise Antibodies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Pharvaris B.V. logo
PHVS
Pharvaris B.V.
1.4$29.01+2.3%$923.52 millionN/A0.00News Coverage
FDMT
4D Molecular Therapeutics
1.3$34.42+9.5%$918.81 millionN/A0.00
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$13.89+2.8%$910.67 millionN/A0.00Gap Down
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$24.27+11.3%$851.85 millionN/A0.00Insider Selling
Analyst Revision
PHAR
Pharming Group
0.0$12.80+3.6%$816.72 millionN/A0.00Gap Up
FNCH
Finch Therapeutics Group
0.3$17.10+0.5%$806.18 millionN/A0.00News Coverage
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$21.84+6.2%$793.40 millionN/A0.00Analyst Revision
Inventiva logo
IVA
Inventiva
1.4$14.35+0.6%$554.34 millionN/A0.00News Coverage
SGTX
Sigilon Therapeutics
1.4$17.43+1.9%$548.92 millionN/A0.00
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$12.59+5.0%$541.36 millionN/A0.00Analyst Revision
News Coverage
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$17.74+6.7%$445.72 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$14.50+2.6%$443.53 millionN/A0.00
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$14.81+4.5%$436.66 millionN/A0.00
NexImmune logo
NEXI
NexImmune
2.0$18.74+4.7%$426.49 millionN/A0.00
Landos Biopharma logo
LABP
Landos Biopharma
1.8$10.15+2.2%$407.20 millionN/A0.00
PRTG
Portage Biotech
0.0$28.97+0.9%$350.05 millionN/A0.00
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$5.60+4.1%$306.31 millionN/A-2.98
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.99+1.1%$296.84 millionN/A-2.76
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$10.53+0.1%$262.22 millionN/A0.00
LBPH
Longboard Pharmaceuticals
1.9$12.99+23.2%$219.75 millionN/A0.00Analyst Revision
Annovis Bio logo
ANVS
Annovis Bio
0.0$25.07+5.9%$174.16 millionN/A0.00
GANX
Gain Therapeutics
1.0$14.00+0.1%$158.63 millionN/A0.00Analyst Report
News Coverage
Gap Down
Trading Halted
VINC
Vincerx Pharma
1.0$18.62+2.4%$152.78 millionN/A0.00
LGVN
Longeveron
0.3$6.92+1.6%$129.45 millionN/A0.00News Coverage
EVAX
Evaxion Biotech A/S
1.7$6.40+4.8%$122.87 millionN/A0.00Analyst Revision
Gap Down
UPC
Universe Pharmaceuticals
0.0$4.22+10.0%$91.79 millionN/A0.00
VRDN
Viridian Therapeutics
1.7$15.73+0.4%$61.47 millionN/A0.00Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.56+1.1%$55.88 millionN/A0.00
VIRI
Virios Therapeutics
1.3$5.99+3.0%$49.90 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.72+4.0%$43.82 millionN/A0.00News Coverage
VLON
Vallon Pharmaceuticals
0.3$4.44+5.0%$30.24 millionN/A0.00High Trading Volume
VRPX
Virpax Pharmaceuticals
0.3$4.78+1.7%$23.64 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$39.73+15.5%$18.44 millionN/A0.00Gap Up
VYNT
Vyant Bio
0.0$3.71+8.4%$15.16 millionN/A0.00
BCTX
BriaCell Therapeutics
0.0$3.92+32.9%$3.03 millionN/A0.00High Trading Volume
News Coverage
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.05+5.6%$0.00N/A0.00
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.72+8.1%$0.00N/A0.00Gap Up
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08+0.0%$0.00N/A0.00
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06+0.0%$0.00N/A0.00
RPHM
Reneo Pharmaceuticals
0.0$12.75+8.9%$0.00N/A0.00High Trading Volume
Gap Up
SCPS
Scopus BioPharma
1.4$7.58+0.1%$0.00N/A0.00Gap Down
VECT
VectivBio
0.0$17.74+36.6%$0.00N/A0.00High Trading Volume
News Coverage
Gap Up
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.